Azacitidine, a DNMT inhibitor, is not therapeutically effective in CLL, and a phase II clinical trial of azacitidine in fludarabine-refractory CLL was terminated prematurely due to lack of response and slow recruitment [103]. Here, DNMT1 is linked to B-cell chronic lymphocytic leukemia.